Pinatuzumab vedotin
Pinatuzumab Vedotin
Pinatuzumab Vedotin (pronunciation: pi-na-tu-zu-mab ve-do-tin) is a type of antibody-drug conjugate used in the treatment of cancer. It is currently under investigation for its potential use in treating non-Hodgkin lymphoma and diffuse large B-cell lymphoma.
Etymology
The name "Pinatuzumab Vedotin" is derived from its components. "Pinatuzumab" is a monoclonal antibody that targets the protein CD22, which is often found on the surface of B cells. "Vedotin" refers to the drug that is attached to the antibody, which is designed to kill cancer cells.
Mechanism of Action
Pinatuzumab Vedotin works by binding to the CD22 protein on the surface of B cells. Once bound, the drug is internalized by the cell, where it releases its cytotoxic payload. This causes the cell to die, reducing the number of cancerous B cells in the body.
Related Terms
See Also
External links
- Medical encyclopedia article on Pinatuzumab vedotin
- Wikipedia's article - Pinatuzumab vedotin
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski